Ishares Msci Spain ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Ishares Msci Spain ETF trades at $62.65, while Regeneron Pharmaceuticals Inc trades at $793.6 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Ishares Msci Spain ETF pays none. Which is the better fit depends on your goals.
| EWP | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $62.66 | $812.27 |
52-Week Low | $47.02 | $545.94 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
EWP is trading at $62.66, up 0.58% with a bullish technical signal driven by strong moving average support. The stock shows mixed momentum with overbought RSI readings but positive ADX trend strength. Recent corporate actions include a $0.92 dividend scheduled for June 2026. European market sentiment remains influenced by ECB policy decisions and energy price volatility.
The stock's outlook balances technical strength against fundamental data gaps. European economic resilience and potential short-squeeze dynamics offer upside, while overbought conditions and geopolitical risks present near-term headwinds. Dividend income provides additional shareholder value, though comprehensive financial metrics are needed for full fundamental assessment.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →